News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
21,741 Results
Type
Article (826)
Company Profile (1)
Press Release (20914)
Section
Business (6412)
Career Advice (11)
Deals (1331)
Drug Delivery (1)
Drug Development (2891)
FDA (426)
Job Trends (249)
News (11260)
Policy (1062)
Tag
2024 Biotech Beach Standard (1)
Academia (55)
Accelerated approval (1)
Allergies (8)
Alliances (2136)
ALS (4)
Alzheimer's disease (28)
Antibody-drug conjugate (ADC) (7)
Approvals (440)
Artificial intelligence (8)
Autoimmune disease (2)
Automation (1)
Bankruptcy (6)
Best Places to Work (197)
Biosimilars (3)
Biotechnology (3)
Bladder cancer (6)
Brain cancer (1)
Breast cancer (11)
Cancer (86)
Cardiovascular disease (3)
Career advice (10)
CAR-T (4)
Cell therapy (13)
Clinical research (2414)
Collaboration (30)
Compensation (10)
COVID-19 (114)
CRISPR (2)
C-suite (8)
Cystic fibrosis (4)
Data (88)
Denatured (2)
Diabetes (7)
Diagnostics (149)
Digital health (3)
Drug discovery (3)
Drug pricing (1)
Drug shortages (1)
Duchenne muscular dystrophy (3)
Earnings (2391)
Events (2549)
Executive appointments (22)
FDA (489)
Funding (22)
Gene editing (3)
Gene therapy (15)
GLP-1 (12)
Government (137)
Grass and pollen (1)
Guidances (4)
Healthcare (727)
IgA nephropathy (3)
Immunology and inflammation (1)
Indications (5)
Infectious disease (120)
Inflammatory bowel disease (4)
Influenza (1)
Intellectual property (3)
Interviews (2)
IPO (475)
Job creations (70)
Job search strategy (10)
Kidney cancer (3)
Layoffs (9)
Legal (208)
Lung cancer (17)
Lymphoma (11)
Manufacturing (16)
MASH (2)
Medical device (404)
Medtech (404)
Mergers & acquisitions (878)
Metabolic disorders (14)
Multiple sclerosis (4)
Neurodegenerative disease (1)
Neuroscience (45)
NextGen: Class of 2025 (86)
Non-profit (61)
Northern California (69)
Obesity (4)
Opinion (1)
Ovarian cancer (3)
Pancreatic cancer (4)
Parkinson's disease (7)
Patents (6)
Patient recruitment (6)
Peanut (5)
People (1738)
Pharmaceutical (1)
Phase I (714)
Phase II (1056)
Phase III (873)
Pipeline (54)
Podcasts (2)
Postmarket research (64)
Preclinical (298)
Press Release (3)
Prostate cancer (6)
Radiopharmaceuticals (11)
Rare diseases (11)
Real estate (159)
Regulatory (806)
Reports (1)
Research institute (48)
Schizophrenia (1)
Series A (4)
Series B (5)
Southern California (93)
Spinal muscular atrophy (3)
Sponsored (1)
Startups (108)
Supply chain (3)
United States (446)
Vaccines (46)
Venture capitalists (2)
Women's health (2)
Date
Today (4)
Last 7 days (29)
Last 30 days (119)
Last 365 days (1290)
2025 (325)
2024 (1276)
2023 (1422)
2022 (2570)
2021 (2505)
2020 (1729)
2019 (1142)
2018 (934)
2017 (1208)
2016 (930)
2015 (1059)
2014 (838)
2013 (650)
2012 (709)
2011 (809)
2010 (745)
Location
Africa (34)
Arizona (2)
Asia (821)
Australia (166)
California (174)
Canada (43)
China (13)
Colorado (1)
Connecticut (1)
Delaware (4)
Europe (9631)
Florida (7)
Georgia (3)
Idaho (4)
Illinois (11)
India (3)
Indiana (8)
Japan (7)
Maine (1)
Maryland (17)
Massachusetts (100)
Michigan (5)
Minnesota (10)
New Jersey (31)
New Mexico (1)
New York (26)
North Carolina (16)
Northern California (69)
Ohio (2)
Oregon (1)
Pennsylvania (13)
South America (151)
Southern California (93)
Tennessee (6)
Texas (6)
Virginia (2)
Washington D.C. (1)
Washington State (3)
21,741 Results for "poxel sas".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Japan for Q4 2024 and FY 2024 sales forecast
January 31, 2025
·
6 min read
Press Releases
Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy
March 20, 2025
·
6 min read
Business
Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2024 and provided a business update.
May 16, 2024
·
6 min read
Business
Poxel to Report Its 2023 Annual Results by the End of April 2024
POXEL SA announces the publication at the end of April 2024 of its 2023 Annual Results, originally scheduled for April 9, 2024, given the expected completion of a transaction by the end of April.
March 28, 2024
·
3 min read
Press Releases
Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment
January 20, 2025
·
4 min read
Business
Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update
POXEL SA announced its cash position and revenue and provided a corporate update for the twelve months ended December 31, 2023.
February 15, 2024
·
10 min read
Business
Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
POXEL SA reported its cash position, provided a financial and business update for the first quarter ended March 31, 2024, and announced the postponement of its 2023 full-year results release, in view of the expected closing of a transaction.
April 29, 2024
·
9 min read
Press Releases
Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan
January 20, 2025
·
6 min read
Press Releases
Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook
December 9, 2024
·
13 min read
Poxel Provides Corporate Update - December 21, 2023
POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, provides a corporate update.
December 21, 2023
·
5 min read
1 of 2,175
Next
